Clamox(125 mg+31.25 mg)/5 ml

Clamox (125 mg+31.25 mg)/5 ml, commonly known as Co-amoxiclav, is a broad-spectrum antibiotic combination used for the short-term treatment of susceptible bacterial infections. The addition of clavulanic acid protects amoxicillin from breakdown by bacterial enzymes, allowing it to treat infections caused by resistant, beta-lactamase-producing bacteria that amoxicillin alone cannot manage.

Conditions Treated with Clamox (125 mg+31.25 mg)/5 ml

• Upper respiratory tract infections (including ENT): tonsillitis, sinusitis, and otitis media (middle ear infection).
• Lower respiratory tract infections: acute and chronic bronchitis, lobar pneumonia, and bronchopneumonia.
• Genito-urinary tract infections: cystitis, urethritis, and pyelonephritis.
• Skin and soft tissue infections: cellulitis, abscesses, and wound infections caused by susceptible organisms.
• Bone and joint infections: including osteomyelitis.
• Other serious infections: septic abortion, puerperal sepsis, and intra-abdominal sepsis.

Because it covers both Gram-positive and Gram-negative organisms, Co-amoxiclav is often prescribed as a first-line or empirical antibiotic when a mixed or resistant bacterial infection is suspected. It should only be taken under the supervision of a registered physician, and a course should always be completed as prescribed even if symptoms improve early.

Clamox (125 mg+31.25 mg)/5 ml is available in several dosage forms and strengths to suit different age groups, infection severity, and routes of administration.

Clamox (125 mg+31.25 mg)/5 ml belongs to the therapeutic class of Broad Spectrum Penicillins, specifically a beta-lactam antibiotic combined with a beta-lactamase inhibitor.

Mechanism of Action (Pharmacodynamics)

Clamox (125 mg+31.25 mg)/5 ml is an antibacterial combination pairing the aminopenicillin amoxicillin with the beta-lactamase inhibitor clavulanic acid. Amoxicillin works by inhibiting bacterial cell wall synthesis, giving it broad bactericidal activity against many Gram-positive and Gram-negative organisms. However, many resistant bacteria produce beta-lactamase enzymes that break down amoxicillin before it can act.

Clavulanic acid has weak antibacterial activity on its own but binds irreversibly to beta-lactamase enzymes, neutralizing them. By protecting amoxicillin from enzymatic degradation, clavulanic acid restores and extends amoxicillin's effectiveness against otherwise resistant bacterial strains, including certain strains of Staphylococcus aureus, Haemophilus influenzae, E. coli, and Klebsiella species.

Absorption and Distribution (Pharmacokinetics)

The pharmacokinetic profiles of amoxicillin and clavulanic acid are closely matched, allowing them to work in tandem throughout the dosing interval:

• Peak serum concentrations of both components are reached approximately one hour after oral administration.
• Absorption of clavulanic acid is optimized when the combination is taken at the start of a meal.
• Both components exhibit low plasma protein binding, with about 70% remaining free (unbound) in serum, allowing good tissue penetration.
• Doubling the dose approximately doubles the resulting serum concentration, indicating linear (dose-proportional) pharmacokinetics.

Oral Dosage Forms (Tablet and Suspension)

Clamox (125 mg+31.25 mg)/5 ml may be taken without regard to meals; however, absorption of the clavulanate component is enhanced when it is taken at the start of a meal. To minimize the risk of gastrointestinal upset, it is generally recommended to take each dose at the beginning of a meal, with doses spaced evenly throughout the day.

IV Injection

The intravenous formulation is intended strictly for IV use and is not suitable for intramuscular or subcutaneous injection. The reconstituted solution can be administered either by:

• Slow intravenous injection over approximately 2 minutes, or
• Slow intravenous infusion over approximately 30 minutes.

The reconstituted vial must be used within 20 minutes of preparation; any unused portion should be discarded after this time.

• Anticoagulants (e.g. Warfarin): Co-amoxiclav has been reported to prolong bleeding time and prothrombin time in some patients. Concurrent use with oral anticoagulants requires careful monitoring.
• Oral Contraceptives: As with other broad-spectrum antibiotics, Co-amoxiclav may reduce the contraceptive efficacy of oral contraceptive pills. Patients should be advised to use an additional non-hormonal method of contraception during treatment.
• Allopurinol: Concomitant use of allopurinol with amoxicillin increases the likelihood of allergic skin reactions. There is no specific data on the concurrent use of Co-amoxiclav with allopurinol, so this combination should be used with caution.
• Probenecid: May decrease the renal excretion of amoxicillin, resulting in increased and prolonged blood levels; concurrent use is not generally recommended unless directed by a physician.
• Methotrexate: Penicillins, including amoxicillin, may reduce the excretion of methotrexate, potentially increasing its toxicity. Concurrent use requires close monitoring.

Always inform your physician or pharmacist about all medications, supplements, and herbal products you are currently taking before starting Clamox (125 mg+31.25 mg)/5 ml.

Side effects of Co-amoxiclav are generally uncommon and, when they occur, are usually mild and transient in nature.

Common Side Effects

• Diarrhoea
• Nausea and vomiting
• Indigestion
• Oral or vaginal candidiasis (fungal overgrowth)

Gastrointestinal side effects with oral therapy can often be minimized by taking the medicine at the start of meals.

Less Common and Rare Side Effects

• Pseudomembranous colitis
• Hepatitis and cholestatic jaundice (usually reversible)
• Urticarial and erythematous skin rashes
• Erythema multiforme, Stevens-Johnson syndrome, and exfoliative dermatitis (rare but serious)
• Angioedema and anaphylaxis (serious allergic reactions, as seen with other beta-lactam antibiotics)

Seek immediate medical attention if you experience difficulty breathing, facial or throat swelling, severe skin rash, or persistent watery/bloody diarrhoea while on this medication.

Pregnancy

Animal studies involving both oral and parenteral administration of Co-amoxiclav have shown no evidence of teratogenic (birth defect-causing) effects. The drug has been used orally during human pregnancy in a limited number of cases without notable adverse effects. However, as with all medications, Co-amoxiclav should be used during pregnancy only when considered essential by the treating physician.

Lactation

Trace quantities of amoxicillin can pass into breast milk during lactation. While generally considered compatible with breastfeeding in most cases, a physician should be consulted before use, and the infant should be monitored for signs of diarrhoea, rash, or oral thrush.

• Use with caution in patients currently on anticoagulant therapy, as Co-amoxiclav may prolong bleeding and prothrombin time.
• Use with caution in patients with severe hepatic (liver) dysfunction; liver function should be monitored where indicated.
• Dosage adjustment is required in patients with moderate to severe renal impairment.
• During administration of high doses, adequate fluid intake and urinary output should be maintained to reduce the risk of crystalluria (crystal formation in urine).
• Patients with a history of penicillin allergy should inform their physician before starting treatment, given the risk of cross-reactivity with other beta-lactam antibiotics.
• Prolonged use may result in overgrowth of non-susceptible organisms, including fungi.

Overdose with Clamox (125 mg+31.25 mg)/5 ml is unlikely to cause serious harm. If it does occur, gastrointestinal symptoms and disturbances of fluid and electrolyte balance may be evident. Co-amoxiclav can be removed from circulation through haemodialysis if required.

In case of a suspected overdose, seek immediate medical attention or contact the nearest hospital/poison control service.

• Store below 25°C, protected from light and moisture.
• Once reconstituted, the oral suspension should be kept refrigerated (not frozen) and used within 7 days.
• Once reconstituted, the IV injection vial must be used within 20 minutes; discard any unused portion.
• Keep out of reach of children.

• Use with caution in patients currently on anticoagulant therapy, as Co-amoxiclav may prolong bleeding and prothrombin time.
• Use with caution in patients with severe hepatic (liver) dysfunction; liver function should be monitored where indicated.
• Dosage adjustment is required in patients with moderate to severe renal impairment.
• During administration of high doses, adequate fluid intake and urinary output should be maintained to reduce the risk of crystalluria (crystal formation in urine).
• Patients with a history of penicillin allergy should inform their physician before starting treatment, given the risk of cross-reactivity with other beta-lactam antibiotics.
• Prolonged use may result in overgrowth of non-susceptible organisms, including fungi.

The 1.2 gm IV injection should be reconstituted by dissolving the powder in 20 ml of Water for Injection BP.

Do not reconstitute or mix with:

• Dextrose solutions
• Sodium bicarbonate injection solution
• Protein hydrolysates or other proteinaceous fluids
• Blood or plasma
• Intravenous lipid emulsions

However, the reconstituted solution may be injected into the drip tubing of infusion fluids containing glucose, bicarbonate, or dextran, administered over a period of 3–4 minutes.